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Magnetotactic bacteria belong to a group of bacteria that synthesize iron oxide nanoparti-
cles covered by biological material that are called magnetosomes. These bacteria use the
magnetosomes as a compass to navigate in the direction of the earth’s magnetic field.This
compass helps the bacteria to find the optimum conditions for their growth and survival.
Here, we review several medical applications of magnetosomes, such as those in magnetic
resonance imaging (MRI), magnetic hyperthermia, and drug delivery. Different methods
that can be used to prepare the magnetosomes for these applications are described. The
toxicity and biodistribution results that have been published are summarized. They show
that the magnetosomes can safely be used provided that they are prepared in specific
conditions. The advantageous properties of the magnetosomes compared with those of
chemically synthesized nanoparticles of similar composition are also highlighted.
Keywords: magnetosomes, magnetic hyperthermia, magnetotactic bacteria, cancer, heat therapy, thermotherapy
INTRODUCTION
Magnetosomes are intracellular structures produced by magne-
totactic bacteria, which comprise magnetic nanoparticles sur-
rounded by lipid bilayer membrane. They have attracted much
attention for biotechnological applications. This is due to a series
of appealing properties summarized below that are not usually
found in chemically synthesized nanoparticles.
(i) The magnetosomes are magnetic nanoparticles, which pos-
sess a narrow size distribution and uniform morphology
when the magnetotactic bacteria are cultivated in optimum
conditions, i.e., essentially using a low oxygen concentration
(varied between 0.25 and 10 mbar, Heyen and Schüler, 2003)
during the growth. In these conditions, the magnetosome
size distribution can be as small as ~10 nm with magne-
tosome sizes typically lying between 45 and 55 nm for the
most commonly studied species of magnetotactic bacteria
(AMB-1 and MSR-1) (Bazylinski and Frankel, 2004; Taylor
and Barry, 2004).
(ii) The core of the magnetosomes is usually composed of mag-
netite (Fe3O4) that can oxidize into maghemite (γFe2O3).
The magnetosome core is also usually of high levels of purity
and crystallinity (Bazylinski and Frankel, 2004).
(iii) The magnetosomes are usually large single magnetic
domain nanoparticles. This leads to a magnetic moment
that is thermally stable at physiological temperature. There-
fore, it produces better magnetic properties than those
found in chemically synthesized iron oxide nanoparticles
that are usually superparamagnetic and possess a ther-
mally unstable magnetic moment. It also yields high values
of the coercivity (H c ~ 20–40 mT) and ratio between the
remanent and saturation magnetization (M r/M s ~ 0.4–0.5)
(Pan et al., 2005; Alphandéry et al., 2008). In spe-
cific conditions described below, these magnetic prop-
erties result in higher heating capacities and bet-
ter magnetic resonance imaging (MRI) contrast agents
for the magnetosomes than for chemically synthesized
nanoparticles.
(iv) The magnetosomes are usually arranged in chains inside the
bacteria. This arrangement is stable enough to be preserved
even after disrupting the bacteria to isolate the magne-
tosomes. Such arrangement is appealing since it prevents
aggregation and yields a high rate of internalization within
human cells, two properties that are usually desired for
medical applications (Alphandéry et al., 2011b, 2012a).
(v) The magnetosomes are covered by biological material made
of a majority of lipids and a minority of proteins. This bio-
logical coating results in negatively charged magnetosomes
with a good dispersion in water (Alphandéry et al., 2011b,
2012a). By contrast, chemically synthesized nanoparticles
are not naturally coated and need to be stabilized, for exam-
ple, by being covered with dextran or PEG molecules. This
usually makes their synthesis more complicated than that of
the magnetosomes.
(vi) The magnetosomes can easily be functionalized, due to the
presence of various chemical groups at their surface (Sun
et al., 2011).
(vii) Methods have been published that enable to produce a large
quantity of magnetosomes up to 170 mg/L/day of magneto-
somes (Matsunaga et al., 1990, 1996; Yang et al., 2001; Heyen
and Schüler, 2003; Sun et al., 2008a; Liu et al., 2010; Zhang
et al., 2011; Alphandéry et al., 2012b).
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(viii) When they are prepared in specific conditions, the magne-
tosomes possess a high biocompatibility and a low toxicity
(Xiang et al., 2007; Sun et al., 2010).
(ix) Finally, magnetosomes are obtained by cultivating magne-
totactic bacteria in a growth medium, which is not toxic (for
example, ATCC medium 1653 for the AMB-1 species). This
contrasts with the use of toxic products often used during
the preparation of chemically synthesized nanoparticles.
PREPARATION OF SUSPENSIONS OF MAGNETOTACTIC
BACTERIA AND BACTERIAL MAGNETOSOMES
Depending on the type of application, different types of suspen-
sions containing either magnetotactic bacteria or isolated magne-
tosomes can be prepared. For example, for targeting tumors, it has
been suggested to use suspensions of living magnetotactic bacteria,
which are administered intravenously and are naturally attracted
by the anoxic environment of the tumor (Benoit et al., 2009). How-
ever, the use of living magnetotactic bacteria for medical applica-
tions will unlikely be accepted by regulatory agencies (FDA in the
USA, EMA in Europe) and this review focuses on magnetosomes
that will more likely be accepted for clinical trials. For treating
cancers using magnetic hyperthermia, it has been suggested to
use suspensions containing chains of magnetosomes (chains of
magnetic nanoparticles) extracted from magnetotactic bacteria
(Alphandéry et al., 2011a,b, 2012a, 2013). For other applications,
the magnetosomes that have been used have been isolated from
magnetotactic bacteria and treated to remove biological material
surrounding them. They have then been coated with lipids for
stabilization (Yoshino et al., 2007). To prepare suspensions con-
taining living whole magnetotactic bacteria, AMB-1, MSR-1, or
MS-1 strains can be purchased from the ATCC or DSMZ cul-
ture collection with a growth protocol, which is provided. A TEM
(transmission electron microscopic) image of a typical whole
magnetotactic bacterium containing several chains of magneto-
somes is presented in Figure 1A. Among the different strains of
magnetotactic bacteria, MSR-1 has achieved the highest yield of
magnetosome production (170 mg/L/day) (Zhang et al., 2011),
and therefore seems to be a promising strain for medical applica-
tions, which require a large quantity of magnetosomes. To obtain
suspensions containing extracted chains of magnetosomes such as
those shown in Figure 1B, the latter can be isolated from magneto-
tactic bacteria using either sonication (Taoka et al., 2006; Sun et al.,
2008b; Alphandéry et al., 2011b), a treatment with sodium hydrox-
ide (Philipse and Maas, 2002), with a French press (Grünberg et al.,
2004; Matsunaga et al., 2007; Xiang et al., 2007), or with a pres-
sure homogenizer (Guo et al., 2011; Tang et al., 2012). Different
methods have also been suggested to purify the suspension of mag-
netosomes after extraction involving either magnetic separation of
the magnetosomes from the cellular debris (Grünberg et al., 2001;
Alphandéry et al., 2011b, 2012a), a treatment with proteinase K to
remove surface proteins (Guo et al., 2011), phenylmethylsulfonyl
fluoride to inhibit the activity of the protease, DNase I to remove
DNA (Sun et al., 2007). The most commonly used method of
sterilization for magnetosome suspensions is gamma rays (Guo
et al., 2011). The magnetosomes can be stabilized in water. Before
being administered to human, the suspensions of magnetosomes
also need to be characterized. The biological material surrounding
the magnetosomes can be characterized using chromatography,
infrared spectroscopy, SDS Page, and mass spectroscopy (Grün-
berg et al., 2004). TEM can be used to measure the size of the
FIGURE 1 |Transmission electron microscopy images of a single magnetotactic bacterium (A) of chains of magnetosomes extracted from whole
magnetotactic bacteria (B) of individual magnetosomes detached from the chains by heat and SDS treatment (C).
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magnetosomes and to verify the high level of crystallinity of the
magnetosome core. Magnetic measurements could also be carried
out to detect the Verwey transition, which would reveal the pres-
ence of magnetite in the magnetosomes (Alphandéry et al., 2008).
Finally, it is also possible to obtain suspensions of individual mag-
netosomes isolated from magnetotactic bacteria (Figure 1C), in
which most of the biological material has been removed by heat-
ing the suspensions of magnetosomes during 5 h at 90°C in the
presence of 1% SDS (Alphandéry et al., 2011b, 2012a).
TOXICITY AND BIODISTRIBUTION OF BACTERIAL
MAGNETOSOMES
The cytotoxicity of bacterial magnetosomes was found to depend
strongly on the type of cell tested. For Hepatoma H22 cells (liver
cancer cells) and promyelocytic HL60 cells (leukemia cells), the
bacterial magnetosomes began to show signs of cytotoxicity at rel-
atively low magnetosome concentrations of 9µg/mL (Sun et al.,
2010). On the other hand, for fibroblasts and breast cancer cells,
such as EMT-6 cells or MDA-MB-231 cells, the magnetosomes
were not cytotoxicity below ~1 mg/mL (Xiang et al., 2007; Sun
et al., 2010; Alphandéry et al., 2011b). The cytotoxicity was also
found to depend on the incubation time (Alphandéry et al., 2008).
Indeed, for magnetosome concentrations higher than 1 mg/mL,
cytotoxicity was found to be low when the incubation time was
shorter than 24 h. On the other hand, for magnetosome concen-
trations lower than 1 mg/mL, cytotoxicity remained low even for
longer incubation times than 24 h. The cytotoxicity of the mag-
netosomes seems to be comparable to that of superparamagnetic
iron oxide nanoparticles (SPION), which were found to be cyto-
toxic above a concentration of 100µg/mL (Karlsson et al., 2008;
Ankamwar et al., 2010; Singh et al., 2010). The acute toxicity of the
bacterial magnetosomes was also studied. It was found that for an
intravenous administration of bacterial magnetosomes, rats could
survive for a maximum quantity of magnetosomes administered
of 480 mg/kg (Liu et al., 2012). This quantity of nanoparticles is
higher than that of 135 mg/kg found for SPION (Liu et al., 2012).
The immunotoxicity of the magnetosomes was also reported. For
that, 1 mg of a suspension of bacterial magnetosomes (magnetic
nanoparticles) was administered in the ears of rabbits and rabbit
temperatures were monitored (Sun et al., 2010). It was found that
rabbit temperatures did not increase following the administration
of the suspensions of magnetosomes. This result together with
other findings presented in reference (Sun et al., 2010) support
the idea that the magnetosomes are not pyrogenic when they are
prepared in the specific conditions described in Sun et al. (2010).
Regarding the biodistribution of the magnetosomes, different
situations can arise. The magnetosomes could be metabolized
by the organism and transformed into free iron. They may also
remain in the form of crystallized nanoparticles. In both cases,
free iron or crystallized magnetosomes can either accumulate in
the organism or be eliminated in the feces or urines. In order
to understand the biodistribution of the magnetosomes, the latter
have been mixed with proteins from bovine pancreas that simulate
the activity of lysosomes. It was observed that the magnetosomes
were degraded by the proteases after 28 days, which suggests that
lysosomes degrade the magnetosomes (Liu et al., 2012). Magne-
tosomes have also been administered intravenously in rats (Sun
et al., 2009) and mice (Liu et al., 2012), and it was found that
they end up in the lysosomes of liver and spleen (Sun et al., 2009;
Liu et al., 2012). These results suggest that the reticuloendothelial
system removes the magnetosomes from bloodstream and that
the magnetosomes are then transformed into free iron (Sun et al.,
2009). In this study (Sun et al., 2009), the magnetosomes were
neither found in the feces nor in the urine or rats. However, in
other studies, magnetosomes have been found in the feces of rats
following intratumoral administration (Alphandéry et al., 2011b),
or intravenous administration, as observed by TEM observation
of the feces (unpublished results obtained by us). We can con-
clude that after being administered in the organism, a portion of
the magnetosomes is most probably transformed into free iron
while another portion remains in a crystallized form and is elim-
inated in the feces. However, more studies are necessary to better
understand the magnetosome biodistribution.
APPLICATIONS OF MAGNETOSOMES IN MRI, MAGNETIC
HYPERTHERMIA, AND DRUG DELIVERY
MAGNETIC RESONANCE IMAGING
Several studies report the use of bacterial magnetosomes as pos-
itive or negative contrast agents. Benoit et al. (2009) have shown
using MRI that magnetotactic bacteria have a natural tendency to
target tumors in mice when they are administered intravenously.
In this study, magnetotactic bacteria were visualized in tumors
using MRI. A portion of the magnetosomes was shown to gener-
ate T 1 (longitudinal relaxation times)-weighted positive contrast,
improving the visualization of the magnetotactic bacteria in the
tumors. Another interesting aspect of this report resides in the
finding that small magnetosomes of ~25 nm in mean sizes pro-
duce a positive contrast while large magnetosomes of mean sizes
~50 nm do not produce such contrast. For the small magneto-
somes, the T 1-weighted MRI signal is also found to increase with
increasing bacterial concentrations provided the bacterial con-
centration remains below a threshold of 0.5 1010 cells/mL. Above
0.5×1010 cells/mL, the T 1-weighted MRI signal decreases due to
the competing T 2 (transverse relaxation times) effect. In general,
good contrast agents are characterized by very high relaxivities (the
inverse of theT 2 relaxation time, usually designated as r2) and very
short values of T 2. Such high values of r2 can be reached with the
magnetosomes. Indeed, it has been shown that both magneto-
somes enclosed in a gel and ferrimagnetic nanoparticles different
from ferridex and with similar properties than the magnetosomes
possess values of r2 as high as 1175 and 324 mM s−1, respectively
(Hu et al., 2010; Lee et al., 2011). These two values are larger than
the value of r2 ~ 133 mM s−1 found for chemically synthesized
nanoparticles ferridex, which are currently approved and tested
in the clinic as contrast agents for MRI application (Lee et al.,
2011).
MAGNETIC HYPERTHERMIA
Magnetosomes are also good candidates to treat cancers using
magnetic hyperthermia. Magnetic hyperthermia is a technique
in which magnetic nanoparticles are administered (or sent) to
tumors and then heated under the application of an alternating
magnetic field. The heat induces anti-tumor activity. In order to be
efficient for magnetic hyperthermia, the nanoparticles therefore
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need to produce a large amount of heat. The magnetosomes
possess good heating properties essentially due to their large sizes,
their ferromagnetic behavior at physiological temperature and
their high level of crystallinity. For ferrimagnetic nanoparticles,
the quantity of heat generated under the application of an alter-
nating magnetic field is essentially proportional to the area of their
hysteresis loop, which increases with increasing nanoparticle sizes.
Indeed, in most cases, H c and M r/M s that are proportional to
the area of the hysteresis loops, increase with increasing nanopar-
ticle sizes. The amount of heat produced by the magnetosomes
has been estimated by measuring magnetosome losses per cycles,
which are defined as the magnetosome SAR (specific absorption
rates) divided by the frequency of the applied magnetic field. The
magnetosome losses per cycle were found to increase with increas-
ing magnetic field strength from 0.1 to 0.2 J/kg (joules per kilogram
of iron contained in the heated magnetosomes) for a magnetic field
strength of 6 mT (Hergt et al., 2005, 2008; Dutz et al., 2007; Timko
et al., 2009, 2013), up to 0.5–1 J/kg for a magnetic field strength of
12 mT (Hergt et al., 2005, 2008; Dutz et al., 2007; Sun et al., 2009).
These values are larger than those of SPION essentially when the
magnetic field strength is higher than 10 mT (Alphandéry et al.,
2011a).
The heating mechanisms of the magnetosomes have also been
studied (Alphandéry et al., 2011a). The aim of this study (Arakaki
et al., 2008), was to determine which type of magnetosomes
between the magnetosomes contained in whole magnetotactic
bacteria, the chains of magnetosomes isolated from magnetotac-
tic bacteria, and the individual magnetosomes detached from the
chains by heat and SDS treatments, is the most suitable candi-
date for the magnetic hyperthermia treatment of tumors. There
are essentially two mechanisms that can produce heat when mag-
netosomes are exposed to an alternating magnetic field. They are
either due to the reversal of the magnetosome magnetic moment
or to the physical rotation of the magnetosomes under the appli-
cation of an alternating magnetic field. In order to eliminate the
contribution of the rotation to the heating mechanism of the mag-
netosomes, suspensions of whole magnetotactic bacteria that do
not produce heat by rotation have been exposed to an alternating
magnetic field (Alphandéry et al., 2011a). For such suspensions
of whole magnetotactic bacteria, losses per cycles of 1.1 J/kgFe
at 23 mT and of 8 J/kgFe at 88 mT were measured. In order to
enable the rotation of the chains of magnetosomes, the latter were
extracted from magnetotactic bacteria by sonication. For these
extracted chains of magnetosomes, the losses per cycle increased
to 5 J/kgFe at 23 mT and to 11 J/kgFe at 83 mT (Alphandéry et al.,
2011a), showing that the rotation of the chains of magnetosomes
contributes to the heating mechanism. Finally, the magnetosomes
have been detached from the chains by heat and SDS treatment
to produce suspensions of individual magnetosomes. The values
of the SAR obtained for the individual magnetosomes (5 J/kgFe
at 23 mT and 9 J/kgFe at 83 mT (Alphandéry et al., 2011a) were
relatively similar to those of the chains of magnetosomes. There-
fore, it was not possible to decide which one between the chains of
magnetosomes or the individual magnetosomes would be the best
candidate for in vivo magnetic hyperthermia treatments of tumors
(Alphandéry et al., 2011a). Therefore both types of magnetosomes
were tested in vivo.
FIGURE 2 | Schematic diagram showing the treatment of a mouse
using magnetic hyperthermia. The mouse has a breast tumor
xeno-grafted under its skin. A suspension of magnetosomes is
administered at the center of the tumor; the mouse is then positioned
inside a coil where an alternating magnetic field is applied three times
during 20 min. The tumor disappears 30 days following the treatment as can
be seen in the bottom right photograph.
In order to evaluate the anti-tumor activity of the magneto-
somes (Alphandéry et al., 2011b), 100µL of suspensions contain-
ing either individual magnetosomes or chains of magnetosomes
at a concentration of 10 mg/mL were administered at the center
of MDA-MB-231 breast tumors xeno-grafted under the skin of
mice following the protocol illustrated in the schematic diagram
of Figure 2. The mice were then exposed to an alternating mag-
netic field of average field strength ~20 mT and frequency 198 kHz
three times during 20 min. This produced an increase in the tumor
temperature up to ~43°C. The treatment with the chains of mag-
netosomes yielded the total disappearance of the tumor 30 days
following the treatment in several mice (Figure 2), while that
using the individual magnetosomes did not produce significant
anti-tumor activity (Alphandéry et al., 2011b). The efficacy of the
treatment was attributed on the one hand to the internalization of
the chains of magnetosomes inside the tumor cells that enabled
intracellular heating and hence efficient tumor cell destruction.
On the other hand, the efficacy of the chains of magnetosomes was
reported to arise from their homogenous distribution throughout
the tumor, which is mostly due to their low level of aggregation.
DRUG DELIVERY
Due to the presence of various chemical groups at the surface of
the magnetosomes, it is possible to conjugate drugs such as dox-
orubicin to the magnetosome surface (Sun et al., 2007, 2008b).
Magnetosomes to which doxorubicin is conjugated have been
tested as anti-tumor agents against hepatic cancer. It has been
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shown that by conjugating doxorubicin to the magnetosomes, it
was possible to slightly increase the anti-tumor activity from 79%
for doxorubicin alone up to 87% for doxorubicin bound to the
magnetosomes (Sun et al., 2007, 2008b). The advantage of using
the magnetosomes is mainly due to the decrease in toxicity. While
doxorubicin is highly toxic when it is used alone with a mor-
tality rate of 80%, doxorubicin bound to the magnetosomes is
much less toxic with a mortality rate of 20% (Sun et al., 2007,
2008b). Therefore, there is a large increase in the benefit to risk
ratio when doxorubicin is conjugated to the magnetosomes, show-
ing the potential of drugs conjugated to magnetosomes for cancer
treatments.
OTHER MEDICAL APPLICATIONS OF BACTERIAL
MAGNETOSOMES
Magnetosomes can be used for other applications, for example,
to detect nucleotide polymorphism, which is useful to diagnose
diseases such as cancer, hypertension, or diabetes, to separate cells
or to detect DNA (Arakaki et al., 2008). To separate cells, magnetic
beads or SPION have been tested. However, these two types of
magnetic materials present drawbacks. Magnetic beads are large
and hence prevent cells from dividing and proliferating correctly.
SPION on the other hand are only weakly magnetic due to their
unstable magnetic moment at physiological and room temper-
atures, which makes them poorly efficient to separate cells. By
contrast, the magnetosomes are of smaller sizes than the magnetic
beads and are more strongly magnetic than the SPION due to
their ferrimagnetic properties. This makes them ideal candidates
for applications in cell separation (Arakaki et al., 2008). The mag-
netosomes have also been used for immunoassays, for example,
to detect small molecules such as pollutant, hormones, or toxic
detergents. These molecules have been attached to the magneto-
some surface using antibodies that specifically bind to them. The
complex formed by the magnetosomes and these molecules has
then been detected (Arakaki et al., 2008). Finally, magnetosomes
have been used to extract DNA. For that, they have been modified
and covered with layers of aminosilanes that link DNA. The com-
plex formed by the magnetosomes and DNA has been bound to a
magnetic column and DNA has been collected by elution with a
phosphate buffer (Arakaki et al., 2008).
In conclusion, we have presented in this review several med-
ical applications of the magnetosomes and we have also briefly
described a few methods that can be used to prepare the
magnetosomes for these applications.
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